PDS Biotech Regains Nasdaq Compliance, Resolving Delisting Threat
PDSB has more than doubled off its 52-week low of $0.507.
Summary
PDS Biotechnology announced it has regained compliance with Nasdaq's minimum bid price requirement, eliminating the risk of delisting.
Key Events · Corporate Governance and Compliance · PDSB
-
Regains Nasdaq Compliance
The company received notice from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement, closing the previously disclosed deficiency matter.
-
Removes Delisting Threat
This action removes the immediate threat of delisting from The Nasdaq Capital Market, which had been in effect since February 25, 2026.
Analysis · PDSB · Life Sciences
PDS Biotechnology has successfully resolved the Nasdaq minimum bid price deficiency, which had been a concern since February 2026. This removes the immediate risk of delisting, a critical factor for maintaining investor confidence and market liquidity, especially for a company of this size. The company's stock price is now above the $1.00 threshold.
At the time of this filing, PDSB was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.6M. The 52-week trading range was $0.51 to $1.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.